Trevi Therapeutics TRVI 深 滬
已收盤 12-12 16:00:00 美东时间
12.77
-0.400
-3.04%
華盛通- 最 高13.45
- 今 開13.12
- 成交量 193.60万股
- 最 低 12.707
- 昨 收 13.17
- 總市值 16.35亿
- 52周最高 14.39
- 市盈率 靜 --
- 換手率 1.51%
- 52周最低 3.4715
- 委 比 85.67%
- 總股本 1.28亿
- 歷史最高 14.39
- 量 比 0.73
- 振 幅 5.64%
- 歷史最低 0.46
- 每 手 1
- 風險率 2.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Trevi Therapeutics appoints new CFO
Trevi Therapeutics (TRVI) named David Hastings as its next chief financial officer, effective January 6, 2026. Hastings prior roles include CFO positions at Arbutus, Unilife, and Incyte. Hastings curr...
12-04 20:43
Trevi Therapeutics Appoints Veteran Finance Leader David Hastings as New CFO Starting January 2026
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with
12-04 20:33
美股牛股 | Arrowhead制药飙升23%，行业首个微粒血症商用药物获FDA批准；DeFi大涨20%
Arrowhead制药飙升23%，行业首个微粒血症商用药物获FDA批准，最新财报强劲超预期；DeFi大涨20%，公司宣布QCAD数字信托获批为加拿大首个合规的加元稳定币>>
11-27 16:04
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
Trevi Therapeutics Q3 EPS $(0.08) Beats $(0.10) Estimate
Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 23.08 percent. This is a 38.46 percent increase over losses of $(0.13) per share
11-14 05:12
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
A Peek at Trevi Therapeutics's Future Earnings
Trevi Therapeutics (NASDAQ:TRVI) will release its quarterly earnings report on ...
11-12 23:01
Trevi Therapeutics Completes Key Phase 1 Drug Interaction Study
Trevi Therapeutics (($TRVI)) announced an update on their ongoing clinical stud...
10-11 00:30
